SWOBY (Swedish Orphan Biovitrum AB) Margin of Safety % (DCF FCF Based): -29.14% (As of Jun. 24, 2026)


SWOBY Swedish Orphan Biovitrum AB SWOBY
67 GF Score
Price $23.18
GF Value $17.17
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Margin of Safety % (DCF FCF Based)?

Swedish Orphan Biovitrum AB SWOBY 67 Margin of Safety % (DCF FCF Based) is -29.14% as of Jun. 24, 2026. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $17.17 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2026-06-24), Swedish Orphan Biovitrum AB's Predictability Rank is 2.5-Stars. Swedish Orphan Biovitrum AB's intrinsic value calculated from the Discounted FCF model is $36.83 and current share price is $23.18. Consequently,

Swedish Orphan Biovitrum AB's Margin of Safety % (DCF FCF Based) using Discounted FCF model is -29.14%.

SWOBY vs ZTS: Margin of Safety % (DCF FCF Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB Margin of Safety % (DCF FCF Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Margin of Safety % (DCF FCF Based) falls into.


SWOBY
67GF Score
Swedish Orphan Biovitrum AB SWOBY
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Swedish Orphan Biovitrum AB Margin of Safety % (DCF FCF Based) Calculation

Swedish Orphan Biovitrum AB's Margin of Safety % (DCF FCF Based) for today is calculated as

Margin of Safety % (DCF FCF Based)=(Intrinsic Value: DCF (FCF Based)-Current Price)/Intrinsic Value: DCF (FCF Based)
=(17.95-23.18)/17.95
=-29.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted FCF model with default parameters. The calculation method is the same as Discounted Earnings model except free cash flow are used in the calculation instead of earnings per share.

What does a Margin of Safety % (DCF FCF Based) of -29.14% mean?
Swedish Orphan Biovitrum AB (SWOBY) has a Margin of Safety % (DCF FCF Based) of -29.14% as of Jun. 24, 2026. Margin of Safety % (DCF FCF Based) is the percent difference between the current price and the intrinsic DCF FCF price. View historical data on Swedish Orphan Biovitrum AB.
Is Swedish Orphan Biovitrum AB's Margin of Safety % (DCF FCF Based) too high?
Swedish Orphan Biovitrum AB's current Margin of Safety % (DCF FCF Based) is -29.14%. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Margin of Safety % (DCF FCF Based) compare to ZTS?
Swedish Orphan Biovitrum AB's Margin of Safety % (DCF FCF Based) of -29.14% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Margin of Safety % (DCF FCF Based) for a Drug Manufacturers company?
A good Margin of Safety % (DCF FCF Based) depends on the Drug Manufacturers industry context. However, Margin of Safety % (DCF FCF Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Margin of Safety % (DCF FCF Based) mean?
A high Margin of Safety % (DCF FCF Based) can signal that a stock is expensive relative to its fundamentals. Margin of Safety % (DCF FCF Based) is the percent difference between the current price and the intrinsic DCF FCF price. View historical data on Swedish Orphan Biovitrum AB. Swedish Orphan Biovitrum AB's current Margin of Safety % (DCF FCF Based) is -29.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.17, compared to a current price of $23.18 — trading 35% above its estimated fair value. The current Margin of Safety % (DCF FCF Based) is -29.14%. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Margin of Safety % (DCF FCF Based) calculated?
Margin of Safety % (DCF FCF Based) is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Margin of Safety % (DCF FCF Based) is -29.14% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of $23.18 is trading 35% above its estimated GF Value™ of $17.17. GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.

Key valuation signals for SWOBY:

  • Margin of Safety % (DCF FCF Based): -29.14%
  • GF Value™: $17.17 vs. price of $23.18 (35% above fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score

Get the complete analysis for SWOBY

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.18
Price
$17.17
GF Value